Arix Bioscience PLC - London-based venture capital firm focused on biotechnology companies - Shares suspended from the London Stock Exchange amid the company's acquisition by RTW Biotech Opportunities Ltd, a New York-based investment firm focused on the life sciences sector. Read More
RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Says it completed on Friday its previously announced acquisition of a 25.5% stake in Arix Bioscience PLC for USD57.1 million, equivalent to GBP1.37 per Arix share. Purchase is to support its planned all-share acquisition of Arix's assets. Arix says RTW on January 15 received confirmation from the UK Financial Conduct Authority that it has approved the proposed change of control. Companies say that as planned, Non-Executive Directors Maureen O'Connell and Isaac Kohlberg have resigned from Arix's board, effective Friday. Read More
Arix Bioscience PLC - London-based venture capital firm investing in "breakthrough" biotechnology companies - Expects USD18.6 million net proceeds from its USD680 million sale of Harpoon Therapeutics, a clinical-stage immunotherapy company, to Rahway, New Jersey-based pharmaceutical maker Merck & Co Inc. Anticipates transaction to close in the first half of 2024. Arix Chair Peregrine Moncreiffe says: "Arix has been an investor in Harpoon Therapeutics since 2017, and it is great to see a company that we have been a part of since the early stages move through the clinic and receive recognition for the platform they have worked hard to develop. This acquisition by Merck provides significant potential for bringing life-saving treatment to cancer patients as they enhance their oncology pipeline. In what has been a difficult time across the biotech sector we see this M&A activity as a further sign of market recovery." Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Wednesday said it has agreed to acquire all the assets of fellow London listing Arix Bioscience PLC in exchange for new RTW shares, and to buy a 25.5% stake from Arix's largest shareholder in cash. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down. Read More
Arix Bioscience PLC - venture capital company focused on investing in breakthrough biotechnology companies - Reports a net asset value per share of GBP1.84 as at July 31, down from GBP1.86 as at June 30. Listed portfolio value falls to GBP69 million as at July 31 from GBP71.2 million as at June 30. Read More
(Alliance News) - Arix Bioscience PLC on Thursday announced its net asset value had increased, but that it plans to launch a strategic review concerning issues like its discounted share price. Read More
Arix Bioscience PLC - London-headquartered venture capital company focused on biotechnology companies - Says its portfolio company Disc Medicine has raised USD157.8 million via a placing of 3.0 million new shares and pre-funded warrants to purchase 204,081 shares. Says the shares were sold at USD49.00 per share. Says Disc will use the funds for the research and clinical development of its current or additional product candidates, as well as for working capital. Notes that Arix's holding in Disc has reduced from 3.1% to 2.7% following the placing. Read More
Arix Bioscience PLC - London-based transatlantic venture capital company focused on investing in biotechnology companies that are advancing in life science - Reports its estimated net asset value stood at 177.0 pence per share at April 30. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced this week and not separately reported by Alliance News: Read More
(Alliance News) - Arix Bioscience PLC said on Tuesday that losses were reduced in 2022, but net asset value fell. Read More
(Alliance News) - Arix Bioscience PLC said on Monday its net asset value at January 31 was 180 pence, down from 182p at the end of October, 2022. Read More
(Alliance News) - Arix Bioscience PLC on Friday said that its portfolio company has completed a previously announced merger with Gemini Therapeutics Inc, following the approval of Gemini shareholders. Read More
Arix Bioscience PLC - London-based venture capital investor in biotech firms - Chair Peregrine Moncreiffe buys 78,000 shares at GBP1.04 each, worth GBP81,120 on Wednesday last week. On October 4, Moncreiffe had bought 100,000 shares at 102.94 pence each, worth GBP102,940. Read More
(Alliance News) - Arix Bioscience PLC on Friday said its portfolio company Imara Inc has signed a merger deal with Enliven Therapeutics Inc. Read More